Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeyar Mohammed Ali

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Pharmaceutics|December 23, 2023
<i>CYP3A5*3</i> and <i>CYP3A4*22</i> Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic ApproachZeyar Mohammed Ali, Marinda Meertens, Beatriz Fernández, et al.
Pharmaceutics|September 27, 2025
Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling StudyZeyar Mohammed Ali, Beatriz Fernández-Alarcón, Pere Fontova, et al.
Therapeutic Drug Monitoring|December 8, 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP FormulationAnna Vidal-Alabró, Pere Fontova, Zeyar Mohammed Ali, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Pharmaceutics|December 23, 2023
<i>CYP3A5*3</i> and <i>CYP3A4*22</i> Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic ApproachZeyar Mohammed Ali, Marinda Meertens, Beatriz Fernández, et al.
Pharmaceutics|September 27, 2025
Optimizing Dose Conversion from IR-Tac to LCP-Tac Formulations in Renal Transplant Recipients: A Population Pharmacokinetic Modeling StudyZeyar Mohammed Ali, Beatriz Fernández-Alarcón, Pere Fontova, et al.
Therapeutic Drug Monitoring|December 8, 2025
Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP FormulationAnna Vidal-Alabró, Pere Fontova, Zeyar Mohammed Ali, et al.
Pageof 1